KADIMASTEM LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 494.7 ILa | +1.33% |
|
+6.94% | -16.58% |
| Mar. 28 | Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 28 | IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company | MT |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 24.87M 9.42B |
|---|---|---|---|---|---|
| Net income 2022 | -22M -8.33B | Net income 2023 | -12M -4.54B | EV / Sales 2022 | - |
| Net Debt 2022 | 739K 280M | Net Debt 2023 | 2.17M 821M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.76
x | P/E ratio 2023 |
-2.12
x | Employees | 31 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 39.92% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.33% | ||
| 1 week | +7.17% | ||
| Current month | -0.58% | ||
| 1 month | -10.22% | ||
| 3 months | -11.82% | ||
| 6 months | -14.41% | ||
| Current year | -16.58% |
1 week
461.60
559.90
1 month
435.10570.00
Current year
435.10725.00
1 year
435.101 040.00
3 years
435.107 199.00
5 years
435.1010 490.00
10 years
435.1094 210.00
| Managers | Title | Age | Since |
|---|---|---|---|
Asaf Shiloni
CEO | Chief Executive Officer | 54 | 21-01-31 |
Michel Revel
FOU | Founder | 85 | 08-10-05 |
Uri Ben-Or
DFI | Director of Finance/CFO | 52 | 22-06-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 20-12-16 | |
Tamar Galili
BRD | Director/Board Member | 51 | 22-01-02 |
Ronen Twito
CHM | Chairman | 49 | 20-12-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 494.7 | +1.33% | 209 |
| 24-04-24 | 488.2 | +3.89% | 5,538 |
| 24-04-21 | 469.9 | +1.80% | 20,995 |
| 24-04-18 | 461.6 | -0.22% | 1,012 |
| 24-04-17 | 462.6 | +1.36% | 256 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 07:24 am EDT
More quotes
Kadimastem Ltd is an Israel-based regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The Companyâs technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The Company produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.
| 1st Jan change | Capi. | |
|---|---|---|
| -16.58% | 5.41M | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.34% | 22.2B | |
| -16.53% | 21.23B | |
| -10.09% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- KDST Stock
